Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zealand Pharma A/S (ZLDPF)

Zealand Pharma A/S (ZLDPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,202,510
  • Shares Outstanding, K 51,510
  • Annual Sales, $ 49,770 K
  • Annual Income, $ -102,180 K
  • EBIT $ -113 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.96
  • Price/Sales 476.42
  • Price/Cash Flow N/A
  • Price/Book 3.71
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.43
  • Most Recent Earnings $-0.56 on 11/07/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.81
  • Number of Estimates 1
  • High Estimate -0.81
  • Low Estimate -0.81
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -22.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.5800 +4.87%
on 11/18/24
126.0000 -22.12%
on 11/11/24
-18.4660 (-15.84%)
since 10/21/24
3-Month
93.5800 +4.87%
on 11/18/24
136.7600 -28.24%
on 09/13/24
-35.1960 (-26.40%)
since 08/21/24
52-Week
46.5900 +110.63%
on 11/27/23
141.7420 -30.77%
on 08/16/24
+51.7590 (+111.61%)
since 11/21/23

Most Recent Stories

More News
Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1...

NVO : 102.11 (-3.00%)
LLY : 740.51 (-1.71%)
ZLDPF : 98.1340 (-2.84%)
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

The future of the weight loss market might not revolve around GLP-1 drugs.

BIOA : 18.40 (-0.03%)
LLY : 740.51 (-1.71%)
ZLDPF : 98.1340 (-2.84%)
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money

Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.

LLY : 740.51 (-1.71%)
ZLDPF : 98.1340 (-2.84%)
NVO : 102.11 (-3.00%)
This Rising Biotech Is a Fantastic Weight-Loss Stock to Buy Now

Its pipeline is one of the best among weight loss-focused biotechs right now.

LLY : 740.51 (-1.71%)
ZLDPF : 98.1340 (-2.84%)
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma

Both companies have a clear path to competing successfully in the market.

ZLDPF : 98.1340 (-2.84%)
LLY : 740.51 (-1.71%)
VKTX : 52.33 (+1.55%)
3 Monster Stocks in the Making to Buy Right Now

They're small now, but these stocks could grow much larger.

VRTX : 446.84 (-0.97%)
NVO : 102.11 (-3.00%)
ZLDPF : 98.1340 (-2.84%)
CRSP : 45.96 (-2.75%)
VKTX : 52.33 (+1.55%)
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio

Could Zealand Pharma be a better option for growth-oriented investors?

ZLDPF : 98.1340 (-2.84%)
LLY : 740.51 (-1.71%)
Invest in the GLP-1 Drug Market With This New ETF

The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...

ZLDPF : 98.1340 (-2.84%)
LLY : 740.51 (-1.71%)
NVO : 102.11 (-3.00%)
OZEM : 25.45 (-0.47%)
ALT : 8.45 (+4.97%)
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.

The risk is higher, but so is the upside when it comes to Zealand Pharma.

ZLDPF : 98.1340 (-2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended...

See More

Key Turning Points

3rd Resistance Point 105.5333
2nd Resistance Point 103.2667
1st Resistance Point 102.1333
Last Price 98.1340
1st Support Level 98.7333
2nd Support Level 96.4667
3rd Support Level 95.3333

See More

52-Week High 141.7420
Fibonacci 61.8% 105.3939
Last Price 98.1340
Fibonacci 50% 94.1660
Fibonacci 38.2% 82.9381
52-Week Low 46.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar